CurveBeam AI wins FDA 510(k) for CT-based bone density measurement

CurveBeam AI Limited (ASX: CVB) said the U.S. Food and Drug Administration cleared its CT-based Bone Mineral Density (BMD) technology for multidetector CT scans with patients lying down. The company calls this the first of two FDA steps needed before it can launch SaaS bone-health products. Next it will pursue a separate 510(k) to extend BMD measurement to its HiRise weight-bearing CT platform.

Bone density usually means a separate DXA appointment. An ASX medical-imaging company just cleared the first FDA step to measure BMD from CT scans — and is aiming for a second clearance so its weight-bearing HiRise scanner can add bone-quality data to the same visit surgeons already use for anatomy.

CurveBeam AI Limited, an Australian Securities Exchange company listed as ASX: CVB, said in a Board-authorised announcement dated 15 Sep 2026 — released about 8:17 a.m. Sydney time, while it was still 14 Sep in the U.S. East — that it received U.S. Food and Drug Administration 510(k) clearance for its CT-based Bone Mineral Density technology using multidetector CT (MDCT) supine scans. Bone mineral density, or BMD, is a measure of how much mineral is in bone. A 510(k) is the FDA’s common path to clear a medical device the maker says is substantially equivalent to something already cleared. Multidetector CT is a standard hospital CT scanner; supine means the patient is lying down. That company release is the filing event. These are company claims. This desk did not review the FDA clearance letter.

Greg Brown, CEO and Managing Director, quoted on the same page: this is “our first clearance of the two necessary steps to take our SaaS based bone health products to market.” SaaS here means software sold as a service on top of the company’s scanners. File the quote and the two-step frame as his, via the company. Do not treat bone-health SaaS as live from this MDCT clearance alone.

The company said the clearance establishes an FDA-cleared foundation for future broader BMD SaaS applications across CurveBeam AI’s CT portfolio. File that as the company’s framing. This desk is not inventing a product catalogue, a 510(k) number, or a launch date.

Next, CurveBeam AI said it will pursue FDA clearance to extend BMD measurement to weight-bearing — standing — CT on its HiRise platform. HiRise is the company’s weight-bearing CT scanner for the lower extremity, the legs and feet. The company said a SaaS revenue launch is tied to that HiRise clearance. Regulatory planning, it said, includes assessing the pathway, clinical evidence requirements, and validation work. File those next steps as the company’s. HiRise BMD is not cleared in this announcement.

The company said integrating BMD into a CT exam already taken for orthopaedic evaluation — bone-and-joint care — could support a “one visit, one scan” model and potentially reduce the need for a separate DXA appointment for some patients. DXA, or dual-energy X-ray absorptiometry, is the usual standalone bone-density scan. File the one-visit picture as CurveBeam AI’s claim. This desk is not saying the method beats DXA, replaces it for every patient, or treats osteoporosis.

Longer-term, and only if later clearances and clinical validation arrive, the company said quantitative BMD — a number for bone quality, not just a picture — could become an extra data layer in digital and robotic-assisted orthopaedic surgical planning from the same CT dataset. File that as a contingent company hope. It is not a live product, and it is not a claim robots already use this BMD number.

CurveBeam AI describes itself as a developer and manufacturer of specialised CT imaging equipment with AI-enabled SaaS clinical assessment tools for musculoskeletal care — conditions of bones, joints, and muscles. Corporate office in Melbourne; global operations in Hatfield, Pennsylvania. File the self-description as the company’s about-box.

PRIMARY here: CurveBeam AI Limited’s Board-authorised ASX announcement dated 15 Sep 2026 Sydney — Tier A company source, not a second-hand wire — read on the Aspect Huntley ASX PDF mirror. The MDCT supine BMD clearance, the two-step SaaS frame, and the HiRise next step are company-attributed. NOT claimed: a 510(k) number, that HiRise BMD is already cleared, SaaS pricing, a revenue forecast, that this replaces DXA for all patients, a cure for osteoporosis, that this desk reviewed the FDA letter, a stock tip, or investment advice. Distinct from the already-filed beta-bionics-mint-fda, ataraxis-tau-chemo, nara-health-14m, tandem-health-100m-series-b, and oracle-health-clinical-ai-agent-nurses.